What is Colinz Laboratories Ltd (531210) share price return in the past 10 years?

Colinz Laboratories Ltd share price has appreciated 13.6% annually (CAGR) over the past ten years.

What is the share price of Colinz Laboratories Ltd (531210)?

Company share prices are keep on changing according to the market conditions. The current trading price of Colinz Laboratories Ltd (531210) on 04-May-2026 16:59:59 at 16:59 is 48.30.

What is the P/E ratio of Colinz Laboratories?

The latest standalone P/E ratio of Colinz Laboratories as of 04-May-2026 is 22.64.

What is the P/B ratio of Colinz Laboratories Ltd (531210)?

The latest standalone P/B ratio of Colinz Laboratories Ltd (531210) as of 04-May-2026 is 1.16.

What is the 52-week high and low of Colinz Laboratories Ltd (531210)?

The 52-week high of Colinz Laboratories Ltd (531210) is Rs. 87.91 and the 52-week low is Rs. 36.11.

Colinz Laboratories Ltd (531210) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Colinz Laboratories Ltd (531210)
Brand: Colinz Laboratories

Key Metrics

Market Cap

₹12 Cr.

P/E Ratio

22.64

Price to Book (P/B)

1.16

Price to Sales (P/S)

1.89

EV/EBITDA

3.90

Return on Capital Employed (ROCE)

6.74%

Current Price

₹48.3

Return on Equity (ROE)

5.39%

Return on Assets (ROA)

4.29%

Operating Profit Margin

7.6%

Net Profit Margin

7.61%

Gross Profit Margin

11.5%

Book Value per Share

₹39.9

Sales Growth (YoY)

-7.11%

Sales Growth (3 Years)

-2.06%

Operating Profit Growth (1 Year)

-7.41%

Operating Profit Growth (3 Years)

-5.37%

Net Profit Growth (1 Year)

2.04%

52-Week Low / High

₹36 / 88

Net Profit Growth (3 Years)

13.54%

Dividend Yield

0.00%

Promoter Holding

66.00%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Stock return of Colinz Laboratories Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 12.6% based on the current price.

Q.1 Revenue growth of Colinz Laboratories Ltd?

Colinz Laboratories Ltd revenue growth is -7.1% for FY-2025, which is below its 5-year CAGR of -2.84%, indicating slower growth.

Q.1 Which industry/sub-sector does Colinz Laboratories Ltd belong to?

Colinz Laboratories Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Promoter shareholding and pledge status of Colinz Laboratories Ltd?

Promoters hold 66.00% of the Colinz Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Colinz Laboratories Ltd vs industry peers?

Colinz Laboratories Ltd revenue CAGR is -2.84%, compared to the industry median CAGR of 8.30%, indicating slower growth and losing its market share.

DeciZen - make an informed investing decision on Colinz Laboratories

Based on:

Data

M-Cap below 100cr DeciZen not available

Colinz Laboratories stock performance

Key Ratios

Is Colinz Laboratories Ltd an attractive stock to invest in?

1. Is Colinz Laboratories Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Colinz Laboratories Ltd is a average quality company.

2. Is Colinz Laboratories Ltd undervalued or overvalued?

The key valuation ratios of Colinz Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Colinz Laboratories Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Colinz Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray :

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	3.3%	3.1%	3.3%	3.5%	3.3%	4.3%	6.8%	7.9%	7.7%	6.7%	-
Value Creation Index ⓘ	-0.8	-0.8	-0.8	-0.8	-0.8	-0.7	-0.5	-0.4	-0.5	-0.5	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	8.1	8.1	7.9	7.6	7.5	6.1	7	7.2	7	6.5	6
Sales YoY Gr.	-	-0.6%	-1.9%	-4.1%	-0.5%	-19%	13.8%	2.9%	-1.7%	-7.1%	-
Adj EPS ⓘ	0.3	0.4	0.7	0.3	0.4	0.5	0.7	1.9	1.9	2	2
YoY Gr.	-	48.2%	62.5%	-47.7%	8.8%	21.6%	64.4%	154.1%	2.7%	1%	-
BVPS (₹) ⓘ	17.7	18.4	19.1	19.3	19.3	20.6	21.7	32.3	35.5	37.6	39.9
Adj Net Profit ⓘ	0.1	0.1	0.2	0.1	0.1	0.2	0.3	0.5	0.5	0.5	1
Cash Flow from Ops. ⓘ	0.6	0.1	0.3	0.1	0.6	2.2	0.5	0.4	1	-1.5	-
Debt/CF from Ops. ⓘ	2.8	13.3	1.3	5.8	0.7	0.5	1	0.7	0.6	-0.4	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-2.4%	-2.8%	-2.1%	-7.1%
Adj EPS ⓘ	24.6%	39.4%	38.1%	1%
BVPSⓘ	8.8%	14.3%	20.1%	5.9%
Share Price	13.6%	28.9%	4.7%	-2.4%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	1.5	2.2	3.5	1.8	1.9	2.9	4.5	6	5.7	5.3	5.3
Op. Profit Mgn % ⓘ	5.6	5.1	4.5	4.6	4	5.4	8.4	8.8	7.7	7.6	6.6
Net Profit Mgn % ⓘ	1.2	1.8	2.9	1.6	1.7	3.4	4.9	6.6	6.9	7.5	8.4
Debt to Equity ⓘ	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0	0.1	0.1	0
Working Cap Days ⓘ	226	226	224	220	198	195	130	110	101	148	279
Cash Conv. Cycle ⓘ	122	136	137	145	143	135	89	73	59	50	213

Recent Performance Summary

Net Profit is growing at healthy rate in last 3 years 38.12%

Return on Equity has declined versus last 3 years average to 5.30%

Sales growth has been subdued in last 3 years -2.06%

Sales growth is not so good in last 4 quarters at -4.40%

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	2	-
TTM Sales (₹ Cr.)	6.1	-
BVPS (₹) ⓘ	39.9	-
Reserves (₹ Cr.) ⓘ	7	-
P/BV ⓘ	1.16	-
PE ⓘ	22.64	-

From the Market
52 Week Low / High (₹)	36.11 / 87.91
All Time Low / High (₹)	0.25 / 88.70
Market Cap (₹ Cr.)	11.6
Equity (₹ Cr.)	2.5
Face Value (₹)	10
Industry PE ⓘ	43.4

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Colinz Laboratories - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	8.10	8.05	7.90	7.58	7.54	6.11	6.95	7.15	7.03	6.53
Operating Expenses ⓘ +	7.64	7.64	7.54	7.23	7.23	5.78	6.36	6.55	6.49	6.03
Manufacturing Costs	0.20	0.20	0.35	0.16	0.15	0.20	0.18	0.19	0.19	0.19
Material Costs	3.48	2.94	2.73	2.80	2.74	2.18	2.30	2.29	2.31	2.09
Employee Cost	2.86	2.91	3.15	3.07	3.25	2.39	2.77	2.90	2.79	2.67
Other Costs ⓘ	1.09	1.58	1.31	1.20	1.08	1	1.11	1.17	1.19	1.08
Operating Profit ⓘ	0.45	0.41	0.36	0.35	0.30	0.33	0.59	0.61	0.54	0.50
Operating Profit Margin (%)	5.6%	5.1%	4.5%	4.6%	4.0%	5.4%	8.4%	8.5%	7.7%	7.6%
Other Income ⓘ +	0.10	0.09	0.10	0.12	0.13	0.19	0.17	0.17	0.28	0.30
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0.12	0.12	0.08	0.10	0.07	0.09	0.08	0.05	0.04	0.04
Depreciation ⓘ	0.28	0.27	0.22	0.22	0.19	0.19	0.20	0.13	0.13	0.13
Profit Before Tax ⓘ	0.15	0.12	0.15	0.16	0.18	0.25	0.48	0.60	0.65	0.62
Tax ⓘ	0.06	-0.02	-0.08	0.03	0.05	0.04	0.14	0.14	0.16	0.12
Profit After Tax	0.09	0.14	0.23	0.12	0.13	0.21	0.34	0.46	0.49	0.50
PAT Margin (%)	1.2%	1.8%	2.9%	1.6%	1.7%	3.4%	4.9%	6.4%	6.9%	7.6%
Adjusted EPS (₹)	0.3	0.4	0.7	0.3	0.4	0.6	1.0	1.8	1.9	2.0
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	6.26	6.52	6.75	6.84	6.84	7.29	7.69	8.14	8.95	9.47
Share Capital ⓘ	3.54	3.54	3.54	3.54	3.54	3.55	3.55	2.52	2.52	2.52
Reserves ⓘ	2.71	2.98	3.21	3.30	3.29	3.75	4.14	5.62	6.43	6.96
Debt +	1.60	0.76	0.42	0.68	0.38	0.99	0.48	0.27	0.57	0.64
Long Term Debt	1.60	0	0	0	0	0	0	0	0	0
Short Term Debt	0	0.76	0.42	0.68	0.38	0.99	0.48	0.27	0.57	0.64
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	0.58	0.45	0.68	0.34	0.37	0.54	0.48	0.65	0.60	0.54
Others Liabilities ⓘ	1.32	1.94	1.74	1.31	1.22	1.27	1.28	1.16	1.24	1.16
Total Liabilities ⓘ	9.75	9.67	9.59	9.17	8.81	10.10	9.93	10.23	11.36	11.82
Fixed Assets
Net Fixed Assets ⓘ +	2.88	2.63	2.41	2.21	2.06	2.03	1.86	1.71	1.58	1.70
Gross Block	6.64	6.66	6.66	6.67	6.72	6.88	6.91	6.17	6.17	6.43
Accumulated Depreciation	3.76	4.03	4.25	4.46	4.66	4.85	5.05	4.46	4.60	4.73
CWIP ⓘ	0	0	0	0	0	0	0	0	0	0
Investments ⓘ	0.29	0.41	0.53	0.50	0.36	0.61	0.67	0.66	1.02	1.04
Inventories	2.22	2.16	1.97	1.90	1.69	1.25	0.93	0.94	0.85	0.78
Trade Receivables	1.35	1.47	1.68	1.68	1.49	1.30	1.21	1.13	0.86	0.66
Cash Equivalents ⓘ	1.62	1.63	1.87	1.99	2.60	4.68	5.21	5.73	7	5.55
Others Assets ⓘ	1.40	1.37	1.13	0.90	0.61	0.25	0.06	0.06	0.05	2.08
Total Assets ⓘ	9.75	9.67	9.59	9.17	8.81	10.10	9.93	10.23	11.36	11.82

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	0.58	0.06	0.34	0.12	0.58	2.16	0.47	0.40	1.03	-1.45
PBT ⓘ	0.15	0.12	0.15	0.16	0.18	0.25	0.48	0.60	0.65	0.62
Adjustment ⓘ	0.28	0.29	0.21	0.19	0.13	0.11	0.11	0.03	-0.11	-0.12
Changes in Working Capital ⓘ	0.17	-0.33	0.01	-0.21	0.34	1.88	0.03	-0.07	0.67	-1.75
Tax Paid ⓘ	-0.03	-0.03	-0.03	-0.03	-0.07	-0.08	-0.15	-0.16	-0.18	-0.21
Cash Flow From Investing Activity ⓘ +	-0	-0.01	-0.11	-0.01	-0.04	-0.15	-0.03	0.01	0.01	-0.23
Capex	-0	-0.02	0	0	-0.04	-0.16	-0.04	0	0	-0.26
Net Investments	0	0	-0.11	-0.01	0	0	0	0	0	0.02
Others ⓘ	0	0	0	0	0.01	0	0.01	0.01	0.01	0.01
Cash Flow From Financing Activity ⓘ +	-0.73	-0.03	0.01	0.02	0.06	0.08	0.09	0.11	0.23	0.24
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-0.73	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	-0.03	-0.08	-0.10	-0.07	-0.09	-0.08	-0.05	-0.04	-0.04
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0.09	0.12	0.13	0.17	0.17	0.16	0.27	0.28
Net Cash Flow ⓘ	-0.16	0.02	0.24	0.12	0.60	2.08	0.52	0.52	1.27	-1.45

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	1.52	2.21	3.48	1.79	1.91	2.94	4.53	5.78	5.7	5.39
ROCE (%)	3.27	3.12	3.25	3.45	3.3	4.28	6.76	7.86	7.67	6.74
Asset Turnover Ratio	0.82	0.83	0.83	0.82	0.85	0.65	0.7	0.71	0.65	0.56
PAT to CFO Conversion(x)	6.44	0.43	1.48	1	4.46	10.29	1.38	0.87	2.1	-2.9
Working Capital Days
Receivable Days	58.70	63.80	72.20	80	76.10	82.60	65.50	59.70	51.80	42.50
Inventory Days	105.90	99.30	94.70	92	86.20	87.10	56.80	47.60	46.40	45.50
Payable Days	86.10	63.70	75.30	66.30	47.40	76.30	80.90	89.90	98.80	99.60

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Colinz Laboratories Ltd FAQs

The current trading price of Colinz Laboratories on 04-May-2026 16:59 is ₹48.30.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-May-2026 the market cap of Colinz Laboratories stood at ₹11.61 Cr

The latest P/E ratio of Colinz Laboratories as of 03-May-2026 is 22.64.

The latest P/B ratio of Colinz Laboratories as of 03-May-2026 is 1.16.

The 52-week high of Colinz Laboratories is ₹87.91 and the 52-week low is ₹36.11.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Colinz Laboratories is ₹6.14 ( Cr.) .

About Colinz Laboratories Ltd

Colinz Laboratories was established in 1987, the company is having modern manufacturing facility near Mumbai. The company is equipped with a full fledged in house testing / quality control laboratory.

The company houses well experienced pharmacists / technical personnel in development dept / manufacturing and caters to an ethical promotion of specialty products in India.

The company is having a well experienced marketing team of over 300 personnels and is having expertise in turn key projects (Design, erection & commissioning of pharma formulation plants) Transfer of technical know how (Pilot Batch to Commercial productions).

Business area of the company spreads to:

Pharmaceutical Formulations (of all dosages forms)

Tablets
Capsules
Parenterals
Creams/ Ointments/Lotions
Dry Powder
Liquid Orals
Soft Gelatine Capsules

Therapeutic Segments

Anti Biotics & Anti Bacterials
Anti Hypertensives
Diuretics
Lipid lowering Agents (Cholestrole Reducers)
Anti Emetics etc.

Vetinary formulations

Feed mix
Bolus
Vitamins & Others

Nutraceuticals

Spirulina
Co enzyme Q10
Clucosamine
Lecithin
Vitamins

Herbal Preparations

Pain Balm (Instant relief for all types of pain)
Anti Cold Rub

Ayurvedic Skin Care Creams Treatment of

Pimples
Fairness
Stretch Marks
Cracks

Capsules/Tablets/ Creams/ Powders

Anti Piles
Laxatives
Anti Diabetic
Anti Hypertensive
Antacid
Vigour & Vitality
General Debility

Contract Manufacturing & Technical Know How Product Development

- Product Development & Clinical Research - Technical know how for formulations - Currently Manufacturing for Europeon & Japanese companies

Sourcing API& / Intermediates Turn key products

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Colinz Laboratories Ltd (531210) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Colinz Laboratories Share Price